FIELD: medicine; pharmaceutical industry.
SUBSTANCE: invention relates to medicine, namely to the pharmaceutical industry, and concerns dosage forms (DF) in the form of gel and spray for the treatment or prevention of wound and hospital infections. A drug for the treatment or prevention of hospital and wound infections contains a mixture of recombinant endolysins LysECD7, LysAm24, and LysAp22, at a concentration of 0.03-0.15 wt.%, and auxiliary components. At the same time, the drug in the form of gel contains a gel-forming agent, PEG 1500 or PEG 3000, and a buffer solution with pH of 7.0-8.0. The drug in the form of spray contains Poloxamer 338 or Poloxamer 407, PEG 1500 or PEG 3000, and a buffer solution with pH of 7.0-8.0.
EFFECT: drugs provide a local antibacterial effect by applying them to a wound surface or administering in the abscess cavity, have a wide range of action, without affecting representatives of normal flora of the gastrointestinal tract.
2 cl, 4 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BACTERICIDAL PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION IN THE FORM OF AN ENDOLYSIN-CONTAINING BACTERICIDAL GEL | 2021 |
|
RU2781050C1 |
| BACTERICIDAL PHARMACEUTICAL COMPOSITION FOR PARENTERAL USE IN THE FORM OF LYOPHILIZATE WITH ENDOLYSIN | 2021 |
|
RU2792679C1 |
| MODIFIED ENDOLYSIN AND ANTIBACTERIAL COMPOSITIONS BASED THEREON FOR TREATING INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII, PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI BACTERIA | 2023 |
|
RU2813626C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST BACTERIA PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI, SALMONELLA TYPHI AND STAPHYLOCOCCUS HAEMOLYTICUS (EMBODIMENTS) | 2019 |
|
RU2730613C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING EYE INFECTIONS CAUSED BY METICILLIN-RESISTANT STRAINS OF STAPHYLOCOCCUS AUREUS, WHICH INCLUDES AS ACTIVE INGREDIENT N-TERMINAL CHAP-DOMAIN OF ENDOLYSIN OF BACTERIOPHAGE K STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2715694C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST BACTERIA PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI, SALMONELLA TYPHI AND STAPHYLOCOCCUS HAEMOLYTICUS (EMBODIMENTS) | 2019 |
|
RU2730614C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS ANTIMICROBIAL AGENT DIRECTED AGAINST GRAM-NEGATIVE BACTERIA: PSEUDOMONAS AERUGINOSA, ACINETOBACTER BAUMANNII, KLEBSIELLA PNEUMONIAE AND SALMONELLA TYPHI (EMBODIMENTS) | 2019 |
|
RU2730615C1 |
| ANTIBACTERIAL COMPOSITION (EMBODIMENTS) AND USE OF PROTEIN AS AN ANTIMICROBIAL AGENT DIRECTED AGAINST ACINETOBACTER BAUMANNII BACTERIA, (EMBODIMENTS) | 2019 |
|
RU2730616C1 |
| BACTERIOPHAGE LYTIC ENZYME AND ANTIBACTERIAL COMPOSITION BASED THEREON | 2018 |
|
RU2703043C1 |
| METHOD OF TREATMENT OF INFECTION RELATED TO THE PROVISION OF MEDICAL ASSISTANCE CAUSED BY A CAUSATIVE AGENT OR PATHOGENS WITH MULTIPLE DRUG RESISTANCE | 2017 |
|
RU2664681C1 |
